Related Experiment Video
Updated: Jan 22, 2026

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
Published on: September 6, 2024
A novel rapamycin analog is highly selective for mTORC1 in vivo
Katherine H Schreiber1, Sebastian I Arriola Apelo2,3,4, Deyang Yu3,4,5
1Buck Institute for Research on Aging, Novato, CA, 94945, USA.
Abstract:
Rapamycin, an inhibitor of mechanistic Target Of Rapamycin Complex 1 (mTORC1), extends lifespan and shows strong potential for the treatment of age-related diseases. However, rapamycin exerts metabolic and immunological side effects mediated by off-target inhibition of a second mTOR-containing complex, mTOR complex 2. Here, we report the identification of DL001, a FKBP12-dependent rapamycin analog 40x more selective for mTORC1 than rapamycin. DL001 inhibits mTORC1 in cell culture lines and in vivo in C57BL/6J mice, in which DL001 inhibits mTORC1 signaling without impairing glucose homeostasis and with substantially reduced or no side effects on lipid metabolism and the immune system. In cells, DL001 efficiently represses elevated mTORC1 activity and restores normal gene expression to cells lacking a functional tuberous sclerosis complex. Our results demonstrate that highly selective pharmacological inhibition of mTORC1 can be achieved in vivo, and that selective inhibition of mTORC1 significantly reduces the side effects associated with conventional rapalogs.
Insights
A new compound, DL001, selectively inhibits mTORC1, a key pathway in aging and disease. This selective inhibition reduces side effects commonly seen with rapamycin, offering a safer therapeutic approach.
Area of Science:
- Biochemistry
- Pharmacology
- Aging Research
Background:
- Rapamycin inhibits mechanistic Target Of Rapamycin Complex 1 (mTORC1), extending lifespan and treating age-related diseases.
- Rapamycin's therapeutic potential is limited by off-target inhibition of mTOR complex 2, causing metabolic and immunological side effects.
Purpose of the Study:
- To identify and characterize DL001, a novel rapamycin analog with enhanced selectivity for mTORC1.
- To evaluate the efficacy and safety profile of DL001 in preclinical models.
Main Methods:
- Developed DL001, a FKBP12-dependent rapamycin analog with 40x greater selectivity for mTORC1 over mTORC2 compared to rapamycin.
- Administered DL001 to cell culture lines and C57BL/6J mice to assess mTORC1 inhibition and side effects.
Main Results:
- DL001 demonstrated potent mTORC1 inhibition in vitro and in vivo.
- DL001 treatment in mice preserved glucose homeostasis and showed reduced or no adverse effects on lipid metabolism and the immune system.
- DL001 repressed elevated mTORC1 activity in cells lacking functional tuberous sclerosis complex, restoring normal gene expression.
Conclusions:
- Highly selective pharmacological inhibition of mTORC1 is achievable in vivo using DL001.
- Selective mTORC1 inhibition significantly mitigates the side effects associated with conventional rapalogs, suggesting improved therapeutic potential.
More Related Videos
09:37A RANKL-based Osteoclast Culture Assay of Mouse Bone Marrow to Investigate the Role of mTORC1 in Osteoclast Formation
Published on: March 15, 2018
10:21Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
Published on: September 12, 2019
Related Concept Videos
What is Natural Selection?
Antibiotic Selection
Types of Selection
Frequency-dependent Selection
Limits to Natural Selection
Natural Selection and Adaptation
Beyond physical adaptations,...